JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

Kodu・Aktsiate loetelu・Veru Inc

Veru Inc

Avatud

2.79 -20.29

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.62

Max

3.58

Põhinäitajad
By Trading Economics
Sissetulek	1M -7.9M
Kasumimarginaal	-128.154
Töötajad	210
EBITDA	2.1M -8.1M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+35.14% upside

Turustatistika
By TradingEconomics
Turukapital	-4.8M 70M
Eelmine avamishind	23.08
Eelmine sulgemishind	2.79

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

0.5101 / 0.5239 Toetus ja vastupanu

Veru Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. aug 2025, 17:49 UTC

Suurimad hinnamuutused turgudel

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11. aug 2025, 17:18 UTC

Suurimad hinnamuutused turgudel

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11. aug 2025, 16:25 UTC

Tulu

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11. aug 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11. aug 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11. aug 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11. aug 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11. aug 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11. aug 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11. aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. aug 2025, 20:37 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11. aug 2025, 20:37 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bakkt Holdings 2Q Rev $577.9M >BKKT

11. aug 2025, 20:37 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement 2Q Rev $25.8M >EXOD

11. aug 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11. aug 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11. aug 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11. aug 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11. aug 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11. aug 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11. aug 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11. aug 2025, 16:42 UTC

Omandamised, ülevõtmised, äriostud

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11. aug 2025, 16:27 UTC

Omandamised, ülevõtmised, äriostud

BBVA Says Sabadell Offer Remains in Effect

11. aug 2025, 16:26 UTC

Omandamised, ülevõtmised, äriostud

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11. aug 2025, 16:25 UTC

Omandamised, ülevõtmised, äriostud

Banco de Sabadell Announced TSB Sale on July 1

11. aug 2025, 16:25 UTC

Omandamised, ülevõtmised, äriostud

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Võrdlus sarnastega

Hinnamuutus

Veru Inc Prognoos

Hinnasiht

By TipRanks

35.14% tõus

12 kuu keskmine prognoos

Keskmine 0.5 USD 35.14%

Kõrge 0.5 USD

Madal 0.5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Veru Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Veru Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.5101 / 0.5239Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Veru Inc

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.